CoChat
Sign Up
Cited by 410

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Breast cancer diagnosis: Imaging techniques and biochemical markers

Jafari, Seyed Hamed, Saadatpour, Zahra, Salmaninejad, Arash, Momeni, Fatemeh, Mokhtari, Mojgan, Nahand, Javid Sadri, Rahmati, Majid, Mirzaei, Hamed, Kianmehr, Mojtaba·2018·Journal of Cellular Physiology
DOI 10.1002/jcp.26379
Open this paper in CoChat — free account

Abstract

Breast cancer is a complex disease which is found as the second cause of cancer‐associated death among women. Accumulating of evidence indicated that various factors (i.e., gentical and envirmental factors) could be associated with initiation and progression of breast cancer. Diagnosis of breast cancer patients in early stages is one of important aspects of breast cancer treatment. Among of various diagnosis platforms, imaging techniques are main diagnosis approaches which could provide valuable data on patients with breast cancer. It has been showed that various imaging techniques such as mammography, magnetic resonance imaging (MRI), positron‐emission tomography (PET), Computed tomography (CT), and single‐photon emission computed tomography (SPECT) could be used for diagnosis and monitoring patients with breast cancer in various stages. Beside, imaging techniques, utilization of biochemical biomarkers such as proteins, DNAs, mRNAs, and microRNAs could be employed as new diagnosis and therapeutic tools for patients with breast cancer. Here, we summarized various imaging techniques and biochemical biomarkers could be utilized as diagnosis of patients with breast cancer. Moreover, we highlighted microRNAs and exosomes as new diagnosis and therapeutic biomarkers for monitoring patients with breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.1002/jcp.26379

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 5 references

Research works printed but not linked: 160

  1. 10.1158/0008-5472.CAN-10-0965 · DOI
  2. Alcantara D., 2014, Molecular imaging of breast cancer: Present and future directions, Frontiers in Chemistry, 18, 112
  3. Andreea G. I., 2011, The role of imaging techniques in diagnosis of breast cancer, Journal of Current Health Sciences, 37, 241
  4. 10.1006/mvre.2002.2414 · DOI
  5. Ariazi E. A., 2002, Estrogen‐related receptor α and estrogen‐related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer, Cancer Research, 62, 6510
  6. 10.1158/0008-5472.CAN-14-3361 · DOI
  7. Banikazemi Z., 2017, Diet and cancer prevention: Dietary compounds, dietary MicroRNAs and dietary exosomes, Journal of Cellular Biochemistry, 28, 26244
  8. 10.1002/bjs.4436 · DOI
  9. 10.1177/153537020623100910 · DOI
  10. 10.1016/j.juro.2014.02.035 · DOI
  11. 10.1097/00000658-200105000-00006 · DOI
  12. 10.1186/bcr1201 · DOI
  13. 10.1038/bjc.2011.3 · DOI
  14. 10.1148/radiology.219.1.r01ap16192 · DOI
  15. 10.1007/s10549-012-2346-4 · DOI
  16. 10.1148/radiology.197.3.7480749 · DOI
  17. 10.1007/s003300050281 · DOI
  18. 10.3109/02841859609173447 · DOI
  19. 10.1148/radiol.2473061678 · DOI
  20. 10.1089/dna.2008.0744 · DOI
  21. 10.1200/jco.2015.33.15_suppl.e22262 · DOI
  22. 10.1155/2010/431341 · DOI
  23. 10.1002/1097-0142(19800815)46:4 <939::AID-CNCR2820461315>3.0.CO;2-L · DOI
  24. 10.1002/prca.200780049 · DOI
  25. 10.1038/ncb2173 · DOI
  26. 10.1007/s10549-012-2034-4 · DOI
  27. 10.7150/jca.13141 · DOI
  28. Das B. K., 2006, Role of scintimammography in the diagnosis of breast cancer, The Malaysian Journal of Medical Sciences: MJMS, 13, 52
  29. 10.1038/sj.bjc.6603756 · DOI
  30. 10.1001/archinternmed.2009.440 · DOI
  31. Dehdashti F., 1995, Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG‐PET and in vitro receptor assays, Journal of Nuclear Medicine, 36, 1766
  32. 10.1016/j.jbi.2014.01.010 · DOI · Paper page
  33. 10.1159/000239795 · DOI
  34. 10.1016/j.ejca.2017.01.017 · DOI
  35. 10.1007/s13277-015-3090-2 · DOI
  36. 10.1016/j.bios.2015.03.017 · DOI
  37. 10.1002/ijc.22293 · DOI
  38. 10.1200/JCO.2001.19.3.645 · DOI
  39. 10.1158/1535-7163.MCT-06-0389 · DOI
  40. 10.1038/cgt.2016.34 · DOI
  41. Ferrero‐Poüs M., 2000, Relationship between c‐erbB‐2 and other tumor characteristics in breast cancer prognosis, Clinical Cancer Research, 6, 4745
  42. 10.1148/radiology.213.3.r99dc01881 · DOI
  43. 10.1016/S0092-8674(03)00234-4 · DOI
  44. Fuqua S. A., 2003, Estrogen receptor β protein in human Breast cancer, Cancer Research, 63, 2434
  45. 10.1158/1078-0432.CCR-05-1913 · DOI · Paper page
  46. 10.1007/s00330-009-1699-5 · DOI
  47. Gholamin S., 2017, GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma, Journal of Cellular Physiology, 1, 25793
  48. 10.1002/bjs.5338 · DOI
  49. 10.1097/00004728-199601000-00003 · DOI
  50. Golabchi K., 2017, MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers, Journal of Cellular Physiology, 28, 26070
  51. 10.1186/s13058-016-0753-x · DOI
  52. 10.1148/radiology.187.2.8475297 · DOI
  53. Hashemi Goradel N., 2017, Nanoparticles as new tools for inhibition of cancer angiogenesis, Journal of Cellular Physiology, 25, 26029
  54. 10.1097/SLA.0b013e3181cc939f · DOI
  55. 10.1101/gad.12.1.21 · DOI
  56. Hoseini Z., 2017, NLRP3 inflammasome: Its regulation and involvement in atherosclerosis, Journal of Cellular Physiology, 27, 25930
  57. 10.1158/0008-5472.CAN-05-1783 · DOI · Paper page
  58. Iqbal N., 2014, Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications, Molecular Biology International, 852748, 7
  59. 10.1016/S0002-9440(10)64702-5 · DOI
  60. 10.1016/j.ejrad.2014.03.027 · DOI
  61. 10.18632/oncotarget.16684 · DOI
  62. 10.1158/1078-0432.CCR-04-2609 · DOI
  63. 10.1158/1055-9965.EPI-08-0629 · DOI
  64. 10.1002/jcb.26042 · DOI
  65. Keshavarzi M., 2017, MicroRNAs‐based imaging techniques in cancer diagnosis and therapy, Journal of Cellular Biochemistry, 29, 26012
  66. 10.1007/BF00947973 · DOI
  67. Khanmohammadi R., 2017, Oral tumors in children: Diagnosis and management, Journal of Cellular Biochemistry, 3, 26316
  68. 10.1002/ssu.1033 · DOI
  69. 10.1093/annonc/mdn733 · DOI
  70. Kristiansen G., 2003, CD24 expression is a new prognostic marker in breast cancer, Clinical Cancer Research, 9, 4906
  71. 10.1097/00006231-200603000-00005 · DOI
  72. 10.2463/mrms.6.21 · DOI
  73. 10.1038/jhg.2016.89 · DOI
  74. 10.1586/14737159.2.1.23 · DOI
  75. 10.2528/PIERM10072001 · DOI
  76. 10.1158/1078-0432.CCR-05-1538 · DOI
  77. 10.1210/en.2009-1506 · DOI
  78. 10.1073/pnas.0604614103 · DOI
  79. 10.1007/s00330‐008‐0863‐7 · DOI
  80. 10.4161/cbt.7.6.5966 · DOI
  81. Mashreghi M., 2017, Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis, Journal of Cellular Physiology, 13, 26049
  82. Masoudi M. S., 2017, MiR‐21: A key player in glioblastoma pathogenesis, Journal of Cellular Biochemistry, 20, 26300
  83. 10.1007/s10549-005-9046-2 · DOI
  84. 10.1186/1476-4598-5-24 · DOI
  85. 10.1349/ddlp.2821 · DOI
  86. 10.1126/science.1071884 · DOI
  87. 10.1158/0008-5472.CAN-05-2495 · DOI
  88. 10.1016/j.crad.2012.03.009 · DOI
  89. 10.1148/radiology.169.1.3262228 · DOI
  90. 10.2174/0929867323666160818093854 · DOI
  91. Mirzaei H., 2017, State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia, Journal of Cellular Physiology, 13, 25799
  92. Mirzaei H., 2017, MicroRNA: A novel target of curcumin in cancer therapy, Journal of Cellular Physiology, 15, 26055
  93. 10.1016/bs.acc.2017.06.004 · DOI
  94. Mirzaei H., 2017, MicroRNA: Relevance to stroke diagnosis, prognosis, and therapy, Journal of Cellular Physiology, 9, 25787
  95. 10.1002/jcp.25739 · DOI
  96. Mirzaei H., 2017, Stroke in women: Risk factors and clinical biomarkers, Journal of Cellular Biochemistry, 12, 26130
  97. 10.1038/cgt.2016.45 · DOI
  98. Moradian Tehrani R., 2017, Mesenchymal stem cells: A new platform for targeting suicide genes in cancer, Journal of Cellular Physiology, 13, 26094
  99. Moridikia A., 2017, MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer, Journal of Cellular Physiology, 16, 25801
  100. 10.1007/s12282-016-0708-1 · DOI
  101. 10.1148/radiology.202.2.9015067 · DOI
  102. 10.1109/TUFFC.2014.006707 · DOI
  103. 10.1158/0008-5472.CAN-05-0553 · DOI
  104. 10.1007/s13277-014-2525-5 · DOI
  105. 10.1158/1055-9965.EPI-07-0654 · DOI
  106. Pawlowski V., 2000, Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real‐time reverse transcription‐polymerase chain reaction assay, Clinical Cancer Research, 6, 4217
  107. 10.1056/NEJMoa052911 · DOI
  108. 10.1158/1055-9965.EPI-07-0365 · DOI
  109. Rabieian R., 2017, Plasminogen activator inhibitor type‐1 as a regulator of fibrosis, Journal of Cellular Biochemistry, 18, 26146
  110. 10.1016/j.biopha.2017.01.161 · DOI
  111. Ristimäki A., 2002, Prognostic significance of elevated cyclooxygenase‐2 expression in breast cancer, Cancer Research, 62, 632
  112. 10.1002/pmic.200390058 · DOI
  113. Saadatpour Z., 2016, Molecular imaging and cancer gene therapy, Cancer Gene Therapy, 18, 62
  114. 10.1038/cgt.2016.61 · DOI
  115. 10.1002/ijc.24108 · DOI
  116. Saeedi Borujeni M. J., 2017, Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome, Journal of Cellular Biochemistry, 8, 26271
  117. Saha Roy S., 2012, Role of estrogen receptor signaling in breast cancer metastasis, International Journal of Breast Cancer, 654698, 19
  118. Santos J. C., 2016, Exosomes‐mediate microRNAs transfer in breast cancer chemoresistance regulation, American Journal of Cancer Research, 6, 2129
  119. 10.1016/j.ejca.2010.02.015 · DOI
  120. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 · DOI
  121. 10.1111/j.1365-2559.2011.04034.x · DOI
  122. 10.1096/fj.11-202036 · DOI
  123. Sempere L. F., 2017, Exosomal MicroRNAs in Breast cancer towards diagnostic and therapeutic applications, Cancers, 9, 10.3390/cancers9070071 · DOI
  124. 10.1016/j.gene.2015.01.062 · DOI
  125. 10.18632/oncotarget.2014 · DOI
  126. 10.1016/j.cell.2009.07.011 · DOI
  127. Simonian M., 2017, Circulating miR‐21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker, Journal of Cancer Research
  128. Singh R., 2014, Exosome‐mediated transfer of miR‐10b promotes cell invasion in breast cancer, Molecular Cancer, 13, 1476
  129. 10.1097/01.SLA.0000059969.64262.87 · DOI
  130. 10.1002/path.1436 · DOI
  131. 10.1038/onc.2012.11 · DOI
  132. 10.1186/1471-2407-14-448 · DOI
  133. 10.1148/radiology.201.2.8888235 · DOI
  134. 10.20892/j.issn.2095-3941.2016.0066 · DOI
  135. 10.20892/j.issn.2095-3941.2016.0066 · DOI
  136. 10.1038/srep24502 · DOI
  137. 10.1016/S1470-2045(04)01413-5 · DOI
  138. 10.1073/pnas.0308319100 · DOI
  139. 10.3748/wjg.v16.i36.4611 · DOI
  140. 10.1196/annals.1448.011 · DOI
  141. Toth B., 2008, Circulating microparticles in breast cancer patients: A comparative analysis with established biomarkers, Anticancer Research, 28, 1107
  142. 10.1177/030089160609200609 · DOI
  143. 10.1200/JCO.2001.19.4.992 · DOI
  144. 10.2214/ajr.184.4.01841266 · DOI
  145. 10.2967/jnumed.114.147579 · DOI
  146. Viehweg P., 2000, In situ and minimally invasive breast cancer: Morphologic and kinetic features on contrast‐enhanced MR imaging. Magnetic Resonance Materials in Physics, Biology and Medicine, 11, 129
  147. 10.1200/JCO.2004.04.148 · DOI
  148. 10.3390/ijms15069546 · DOI
  149. 10.1677/ERC-10-0136 · DOI
  150. Wellings E., 2016, Breast cancer screening for high‐Risk patients of different ages and risk—Which modality is most effective, Cureus, 8, 945
  151. 10.1148/radiology.207.3.9609890 · DOI
  152. 10.1186/bcr738 · DOI
  153. 10.1158/0008-5472.CAN-07-5012 · DOI · Paper page
  154. 10.1042/BJ20080328 · DOI
  155. 10.1158/1055-9965.EPI-08-0696 · DOI
  156. 10.1074/jbc.M111.280768 · DOI
  157. 10.1590/S1807-59322011000300014 · DOI
  158. 10.1158/0008-5472.CAN-10-0697 · DOI
  159. 10.1007/s10549-015-3431-2 · DOI
  160. 10.1186/s13058-017-0858-x · DOI

Cited by

Sorted by citations

See all 410

Metadata

Authors
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M.
Venue
Journal of Cellular Physiology
Publisher
Wiley
Published
2018-01-19
Volume
233
Issue
7
Pages
5200-5213
ISSN
  • 0021-9541
  • 1097-4652
DOI
10.1002/jcp.26379
Cited by
410
References
5
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review